Bottomley, Andrew and Pe, Madeline and Sloan, Jeff and Basch, Ethan and Bonnetain, Franck and Calvert, Melanie and Campbell, Alicyn and Cleeland, Charles and Cocks, Kim and Collette, Laurence and Dueck, Amylou C. and Devlin, Nancy and Flechtner, Hans-Henning and Gotay, Carolyn and Greimel, Eva and Griebsch, Ingolf and Groenvold, Mogens and Hamel, Jean-Francois and King, Madeleine and Kluetz, Paul G. and Koller, Michael and Malone, Daniel C. and Martinelli, Francesca and Mitchell, Sandra A. and Moinpour, Carol M. and Musoro, Jammbe and O'Connor, Daniel and Oliver, Kathy and Piault-Louis, Elisabeth and Piccart, Martine and Pimentel, Francisco L. and Quinten, Chantal and Reijneveld, Jaap C. and Schuermann, Christoph and Smith, Ashley Wilder and Soltys, Katherine M. and Taphoorn, Martin J. B. and Velikova, Galina and Coens, Corneel (2016) Analysing data from patient-reported outcome and quality of life endpoints for cancer clinical trials: a start in setting international standards. LANCET ONCOLOGY, 17 (11). E510-E514. ISSN 1470-2045, 1474-5488
Full text not available from this repository. (Request a copy)Abstract
Measures of health-related quality of life (HRQOL) and other patient-reported outcomes generate important data in cancer randomised trials to assist in assessing the risks and benefits of cancer therapies and fostering patient-centred cancer care. However, the various ways these measures are analysed and interpreted make it difficult to compare results across trials, and hinders the application of research findings to inform publications, product labelling, clinical guidelines, and health policy. To address these problems, the Setting International Standards in Analyzing Patient-Reported Outcomes and Quality of Life Endpoints Data (SISAQOL) initiative has been established. This consortium, directed by the European Organisation for Research and Treatment of Cancer (EORTC), was convened to provide recommendations on how to standardise the analysis of HRQOL and other patient-reported outcomes data in cancer randomised trials. This Personal View discusses the reasons why this project was initiated, the rationale for the planned work, and the expected benefits to cancer research, patient and provider decision making, care delivery, and policy making.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | EVEROLIMUS PLUS EXEMESTANE; BREAST-CANCER; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Zentren des Universitätsklinikums Regensburg > Zentrum für Klinische Studien |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 12 Apr 2019 12:24 |
| Last Modified: | 12 Apr 2019 12:24 |
| URI: | https://pred.uni-regensburg.de/id/eprint/3996 |
Actions (login required)
 |
View Item |
